{
  "id": "5c73ad0f7c78d69471000096",
  "type": "list",
  "question": "Which diseases are treated with netarsudil?",
  "ideal_answer": "In 2 large, randomized, double-masked trials, once-daily dosing of netarsudil 0.02% was found to be effective and well tolerated for the treatment of patients with ocular hypertension and open-angle glaucoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29199013",
    "http://www.ncbi.nlm.nih.gov/pubmed/28609185",
    "http://www.ncbi.nlm.nih.gov/pubmed/30323550",
    "http://www.ncbi.nlm.nih.gov/pubmed/27072905",
    "http://www.ncbi.nlm.nih.gov/pubmed/29469601",
    "http://www.ncbi.nlm.nih.gov/pubmed/30007591",
    "http://www.ncbi.nlm.nih.gov/pubmed/29622939",
    "http://www.ncbi.nlm.nih.gov/pubmed/30209441",
    "http://www.ncbi.nlm.nih.gov/pubmed/30028313",
    "http://www.ncbi.nlm.nih.gov/pubmed/29453668"
  ],
  "snippets": [
    {
      "text": "Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase\u00a0Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29199013",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: In 2 large, randomized, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be effective and well tolerated for the treatment of patients with ocular hypertension and open-angle glaucoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29199013",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Netarsudil ophthalmic solution 0.02% (hereafter referred to as netarsudil 0.02%) [Rhopressa\u00ae] is a Rho-associated protein kinase inhibitor that is thought to lower intraocular pressure (IOP) by increasing aqueous humour outflow through the trabecular meshwork. It has been developed by Aerie Pharmaceuticals and was recently approved in the USA for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29453668",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Netarsudil, an inhibitor of Rho kinase and a norepinephrine transporter, has been shown to lower elevated intraocular pressure (IOP) in controlled studies of patients with open-angle glaucoma and ocular hypertension, and in healthy volunteers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29469601",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Once-daily dosing of netarsudil ophthalmic solution 0.02% lowered IOP through increasing trabecular outflow facility and reducing EVP.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29469601",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Netarsudil ophthalmic solution (Rhopressa) for the reduction of elevated intraocular pressure; ertugliflozin (Steglatro) for adults with type-2 diabetes; and lutetium lu 177 dotatate (Lutathera) for certain gastroenteropancreatic neuroendocrine tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29622939",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two recently approved multi-pharmacophoric drugs (e.g., rho kinase inhibitor, Netarsudil; a drug conjugate, Latanoprostene Bunod) and novel aqueous humor drainage devices (iStent and CyPass) are also gaining acceptance for treating POAG/ NTG. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30028313",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ultimately, a search for Rho kinase inhibitors led to the discovery of several molecules of therapeutic interest, leaving us today with 2 new ocular hypotensive agents approved for clinical use: ripasudil in Japan and netarsudil in the United States. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30007591",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30209441",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Once-daily (p.m.) netarsudil ophthalmic solution 0.02% (Rhopressa) is approved in the United States for lowering elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30209441",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\nIn 2 large, randomized, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be effective and well tolerated for the treatment of patients with ocular hypertension and open-angle glaucoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29199013",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28609185",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Netarsudil ophthalmic solution is a novel topical intraocular pressure (IOP)-lowering agent that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of ocular hypertension and open-angle glaucoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30323550",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Once-daily (p.m.) netarsudil ophthalmic solution 0.02% (Rhopressa) is approved in the United States for lowering elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30209441",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of netarsudil 0.02% leading to this first approval for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29453668",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27072905",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date.Netarsudil ophthalmic solution is a novel topical intraocular pressure (IOP)-lowering agent that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of ocular hypertension and open-angle glaucoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30323550",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma.Netarsudil is a novel ROCK/NET inhibitor with high potency in biochemical and cell-based assays, an ability to produce large and durable IOP reductions in animal models, and favorable pharmacokinetic and ocular tolerability profiles.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28609185",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30323550",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In 2 large, randomized, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be effective and well tolerated for the treatment of patients with ocular hypertension and open-angle glaucoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29199013",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To evaluate the efficacy and ocular and systemic safety of netarsudil 0.02% ophthalmic solution, a rho-kinase inhibitor and norepinephrine transporter inhibitor, in patients with open-angle glaucoma and ocular hypertension.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29199013",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "ocular hypertension, open-angle glaucoma"
}